The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development

Toll-Like Receptors Serve as Biomarkers for Early Diagnosis and Prognosis Assessment of Kidney Renal Clear Cell Carcinoma by Influencing the Immune Microenvironment: Comprehensive Bioinformatics Analysis Combined With Experimental Validation

(2022) Xiong Zou et al.   Frontiers in Molecular Biosciences

Targeting Wnt Signaling in Endometrial Cancer

(2021) Iram Fatima et al.   Cancers

Toll-Like Receptors: General Molecular and Structural Biology

(2021) Payam Behzadi et al.   Journal of Immunology Research

Highly Expressed DLL4 and JAG1: Their Role in Incidence of Breast Cancer Metastasis

(2020) Samir F. Zohny et al.   ARCHIVES OF MEDICAL RESEARCH

Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer

(2020) Elena Ivanova et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis

(2020) Shaily Arora et al.   CLINICAL CANCER RESEARCH

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

(2020) Mark R. Middleton et al.   BRITISH JOURNAL OF CANCER

An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study

(2020) Ignacio Romero et al.   GYNECOLOGIC ONCOLOGY

Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy

(2020) David M. Francis et al.   Science Translational Medicine

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models

(2020) Dong-Hoon Yeom et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers

(2019) Elena Bonazzoli et al.   GYNECOLOGIC ONCOLOGY

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells

(2019) Liliana Mendonça et al.   CLINICAL & EXPERIMENTAL METASTASIS

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

(2019) Melvyn T. Chow et al.   IMMUNITY

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

Stable silencing of dll4 gene suppresses the growth and metastasis of esophagus cancer cells by attenuating Akt phosphorylation

(2018) Xianzhi Guo et al.   ONCOLOGY REPORTS

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study

(2018) H Gogas et al.   ANNALS OF ONCOLOGY

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus–Derived Vectors Fosters Dendritic Cell–Mediated T-cell Cross-Priming

(2018) Alfonso R. Sánchez-Paulete et al.   CANCER RESEARCH

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

(2017) Guido J.R. Zaman et al.   MOLECULAR CANCER THERAPEUTICS

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

(2017) Mark B. Faries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

(2016) Peter Ellmark et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

(2016) Luuk van Hooren et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DLL4 overexpression increases gastric cancer stem/progenitor cell self-renewal ability and correlates with poor clinical outcome via Notch-1 signaling pathway activation

(2016) Zhi-Feng Miao et al.   Cancer Medicine

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer

(2015) F. Kuhnert et al.   CANCER RESEARCH

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

(2015) E. G. Chiorean et al.   CLINICAL CANCER RESEARCH

PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a  -Secretase Inhibitor

(2015) K. Wang et al.   CLINICAL CANCER RESEARCH

A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation

(2015) Alexandre Patenaude et al.   MICROVASCULAR RESEARCH

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

(2015) S. Lopez et al.   MOLECULAR CANCER THERAPEUTICS

Jagged–Delta asymmetry in Notch signaling can give rise to a Sender/Receiver hybrid phenotype

(2015) Marcelo Boareto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development

(2015) Ana-Rita Pedrosa et al.   PROSTATE

Abstract 3725: Anti-DLL4 (demcizumab) inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts.

(2014) Wan-Ching Yen et al.   CANCER RESEARCH

The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer

(2014) Hongchun Wang et al.   CLINICA CHIMICA ACTA

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

(2014) Mila Donker et al.   LANCET ONCOLOGY

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

(2014) Linda C Sandin et al.   OncoImmunology

Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1

(2013) Jia Lu et al.   CANCER CELL

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Notch as a hub for signaling in angiogenesis

(2013) Rui Benedito et al.   EXPERIMENTAL CELL RESEARCH

Dll4-Notch signaling in regulation of tumor angiogenesis

(2013) Zhaoguo Liu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The perivascular niche regulates breast tumour dormancy

(2013) Cyrus M. Ghajar et al.   NATURE CELL BIOLOGY

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

(2013) L. C. Sandin et al.   Cancer Immunology Research

Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense

(2012) Shaherin Basith et al.   ARCHIVES OF PHARMACAL RESEARCH

Developmental signaling pathways in cancer stem cells of solid tumors

(2012) Christina Karamboulas et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

(2012) W.-C. Yen et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment--Poor Prognosis or New Therapeutic Opportunity

(2012) L. A. Ridnour et al.   CLINICAL CANCER RESEARCH

“Sprouting angiogenesis”, a reappraisal

(2012) Domenico Ribatti et al.   DEVELOPMENTAL BIOLOGY

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

(2012) D. W. Jenkins et al.   MOLECULAR CANCER THERAPEUTICS

The Clinical Relevance of Rising CA-125 Levels Within the Normal Range in Patients With Uterine Papillary Serous Cancer

(2012) Marina Frimer et al.   Reproductive Sciences

Suppression of Colon Cancer Metastasis by Aes through Inhibition of Notch Signaling

(2011) Masahiro Sonoshita et al.   CANCER CELL

Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells

(2011) T. S. Zhu et al.   CANCER RESEARCH

Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer

(2011) W. Hu et al.   CANCER RESEARCH

Ligand-driven activation of the Notch pathway in T-all and solid tumors: Why Not(ch)?

(2011) Stefano Indraccolo et al.   CELL CYCLE

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

(2009) K El-Sahwi et al.   BRITISH JOURNAL OF CANCER

The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis

(2009) Rui Benedito et al.   CELL

DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency

(2009) Timothy Hoey et al.   Cell Stem Cell

Notch-1 activates estrogen receptor-α-dependent transcription via IKKα in breast cancer cells

(2009) L Hao et al.   ONCOGENE

TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme

(2008) L. Verstrepen et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients

(2008) B. G. Molenkamp et al.   CLINICAL CANCER RESEARCH

Notch signaling regulates tumor angiogenesis by diverse mechanisms

(2008) J Dufraine et al.   ONCOGENE

Expression of Delta-Like Protein 4 in the Human Endometrium

(2007) J. Mazella et al.   ENDOCRINOLOGY